- Focusing on further PQ912 development strategy
Operating costs in H117 were largely in line with our expectations, while a one-off payment was a welcome resolution of Probiodrug’s long-outstanding potential tax liability. Following the overall positive Phase IIa data with PQ912 for Alzheimer’s disease (AD) released in June 2017, Probiodrug reiterated in its H117 report that all strategic options for further development are on the table. Depending on available funding, the company could initiate the next study looking at the long-term treatment of AD patients (the Phase IIa SPAHIR treatment period was three months) or, if a suitable partner emerges, a deal could alleviate the late stage PQ912 development. Our valuation has increased slightly to €496m or €61/share.Vivoryon Therapeutics AG Formerly known as Probiodrug AG. Vivoryon Therapeutics AG, formerly Probiodrug AG, is a Germany-based biopharmaceutical company active in the biotechnology and medical research industry. The Company focuses on the development therapeutic products for the treatment of Alzheimer's disease. It develops drugs to target toxic pyroglutamate-Abeta (pGlu-Abeta) via two modes of action, namely by inhibiting the production of pGlu-Abeta and by clearing existing pGlu-Abeta from the brain. The Company develops specific inhibitors for the enzyme Glutaminyl Cyclase (QC) helping in the creation of pGlu-Abeta and engineers a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Its product pipeline comprises PQ912 and PQ1565, small molecule QC inhibitors, as well as PBD-C06, a pGlu-Abeta specific monoclonal antibody.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.